Repligen (RGEN) Cash from Investing Activities (2010 - 2026)
Repligen's (RGEN) quarterly Cash from Investing Activities came in at -$2.1 million in Q2 2026, up 73.35% year-over-year from -$1.2 million in Q2 2025, and up 47.62% quarter-over-quarter from -$4.0 million in Q1 2026.
Analysis
Repligen (RGEN) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Repligen (RGEN) has reported Cash from Investing Activities for 17 consecutive years, with -$2.1 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Investing Activities rose 73.35% year-over-year to -$2.1 million in Q2 2026; TTM through Jun 2026 was -$222.6 million, a 45.9% decrease from a year earlier, with the FY2025 full-year figure at -$298.5 million, down 245.52% from the prior year.
- Cash from Investing Activities was -$2.1 million for Q2 2026 at Repligen, up from -$4.0 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $64.8 million in Q2 2023 and troughed at -$208.7 million in Q4 2025.
- A 5-year average of -$41.5 million and a median of -$9.1 million in 2023 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities jumped 347.27% in 2023 and slumped 786.25% in 2025, its largest moves.
- Over 5 years, Cash from Investing Activities stood at -$121.3 million in 2022, then slumped by 40.06% to -$169.9 million in 2023, then soared by 61.88% to -$64.8 million in 2024, then sank by 222.32% to -$208.7 million in 2025, then soared by 99.0% to -$2.1 million in 2026.
- The last three Cash from Investing Activities figures came in at -$2.1 million (Q2 2026), -$4.0 million (Q1 2026), and -$208.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 241.68 Bn | 237.61 Bn | 8.34 Bn | 164.00 Mn |
| 2 | Danaher | 147.34 Bn | 142.99 Bn | 3.61 Bn | -10.15 Bn |
| 3 | Agilent Technologies | 43.34 Bn | 41.59 Bn | 1.04 Bn | -1.03 Bn |
| 4 | Illumina | 34.58 Bn | 33.41 Bn | 770.00 Mn | -122.00 Mn |
| 5 | Revvity | 16.31 Bn | 15.29 Bn | 416.87 Mn | -3.51 Mn |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn | -7.06 Mn |
| 7 | Bio-Rad Laboratories | 10.16 Bn | 8.54 Bn | 345.80 Mn | -66.70 Mn |
| 8 | Repligen | 9.77 Bn | 8.75 Bn | 110.04 Mn | -2.09 Mn |
| 9 | 10x Genomics | 9.45 Bn | 8.90 Bn | 112.50 Mn | -7.74 Mn |
| 10 | Bruker | 9.26 Bn | 9.04 Bn | 416.00 Mn | -25.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.09 Mn |
| Mar 31, 2026 | -3.99 Mn |
| Dec 31, 2025 | -208.74 Mn |
| Sep 30, 2025 | -7.78 Mn |
| Jun 30, 2025 | -7.84 Mn |
| Mar 31, 2025 | -74.11 Mn |
| Dec 31, 2024 | -64.76 Mn |
| Sep 30, 2024 | -5.86 Mn |
| Jun 30, 2024 | -7.40 Mn |
| Mar 31, 2024 | -8.36 Mn |
| Dec 31, 2023 | -169.91 Mn |
| Sep 30, 2023 | -8.77 Mn |
| Jun 30, 2023 | 64.83 Mn |
| Mar 31, 2023 | -9.43 Mn |
| Dec 31, 2022 | -121.31 Mn |
| Sep 30, 2022 | -57.49 Mn |
| Jun 30, 2022 | -26.22 Mn |
| Mar 31, 2022 | -28.21 Mn |
| Dec 31, 2021 | -62.28 Mn |
| Sep 30, 2021 | -132.70 Mn |